REGULATORY

Daiichi Sankyo’s Enhertu Clears MHLW Panel, Conditional Nod Expected in March

February 27, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Daiichi Sankyo’s HER2-targeting antibody drug conjugate (ADC) trastuzumab deruxtecan sailed through the review of a key health ministry advisory committee on February 26, with its conditional approval now expected to come as early as next month if all goes well.…

To read the full story

Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020

REGULATORY

MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
WG Members Urge Domestic Biologic Production as National Growth Strategy
March 2, 2026
MHLW Clarifies Up to 12-Year Data Protection for Pediatric Development
March 2, 2026
MHLW Issues 15 Notices Ahead of PMD Act Amendment
March 2, 2026
Celltrion’s Eylea Biosimilar Nears Approval, but Listing Outlook Clouded
February 27, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…